Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
about
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three StudiesUnraveling oxyntomodulin, GLP1's enigmatic brotherAction and therapeutic potential of oxyntomodulinA continued saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activitiesGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesAlbiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiencyEffects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathyAn overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy.Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular diseasePEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction.Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetesGlucagon-like peptide-1, diabetes, and cognitive decline: possible pathophysiological links and therapeutic opportunities.Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrixBoth stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits.Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat HeartExendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways.Liraglutide protects pancreatic β-cells against free fatty acids in vitro and affects glucolipid metabolism in apolipoprotein E-/- mice by activating autophagy.The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice.A meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure.Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts.Exendin-4-loaded PLGA microspheres relieve cerebral ischemia/reperfusion injury and neurologic deficits through long-lasting bioactivity-mediated phosphorylated Akt/eNOS signaling in ratsGlucagon-like peptide-1 inhibits vascular smooth muscle cell dedifferentiation through mitochondrial dynamics regulation.Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma.Therapy in the early stage: incretins.Metabolically-inactive glucagon-like peptide-1(9-36)amide confers selective protective actions against post-myocardial infarction remodelling.Elevated plasma GLP-1 levels and enhanced expression of cardiac GLP-1 receptors as markers of left ventricular systolic dysfunction: a cross-sectional studyNovel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the ratType 2 diabetes mellitus and hypertension: an update.Sweet-taste receptors, low-energy sweeteners, glucose absorption and insulin release.Next-generation GLP-1 therapy: an introduction to liraglutide.Novel GLP-1 receptor agonists for diabetes.Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.Glucagon-like peptide-1 and its cardiovascular effects.Cardiovascular effects of gliptins.Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetes.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose.Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
P2860
Q26777177-A444EBFD-4F21-4037-9A82-88C2CDD6D7CEQ27001704-9298B457-009E-4EA7-81D2-D1DA31973450Q27025870-74A3A032-A800-4027-A994-773FDB33EDD4Q27027240-89C0740E-B44A-4EC4-9071-DB2EFBAAAD85Q28067465-0ED2F5F6-14CC-4A69-AB49-9A861EF85E87Q28740948-CDBCE978-A067-40E3-96DB-20DB823FFCBCQ28742534-6F67020E-B8CC-4A4B-AA08-56A24084570DQ33786150-5AF02B15-44EA-4448-82C1-83CD6F427FBEQ33832036-FA3DA0E7-DD45-416C-849F-A2BF7F70F404Q33939256-9838EAE4-57D1-4604-9E96-84A17C6466D9Q34785887-6EED8D18-A216-49BE-AA3D-4FB46F675EE4Q34994502-EC8EC7AF-C02A-46CA-A6C6-06B93306F0DEQ35070673-6574E8C5-01A9-4511-A9B7-FECED68D23E8Q35132702-77A0077A-AD0E-45A8-B82A-959EE92682C8Q35210037-28BE5EE5-A2FB-4CFB-9536-2E586A4FEDDAQ35670896-FEA7EBBD-BDC4-4C9E-98E4-940440A018BEQ35778740-EABDE7D5-EFAA-4B4F-84DE-529A2B522ED4Q35919653-C7DBF8F0-D3C1-4EC3-9246-1E22D27EF303Q36051056-F95C4A3D-8BFE-4554-BCD7-6C1C1B405712Q36090588-AE3501FB-A2FF-433C-95FB-B571695DE1E2Q36176495-B11A2F4E-F23F-41EB-A23F-91BE8DCE039AQ36254337-1108B84E-6FF4-4AAD-B6CF-8F469C46637CQ36642535-FB6F8DBC-07A7-4E75-A9A9-520EF56CC19EQ36718544-0D359E09-20A6-4E0F-A483-5CFB76BE9BD1Q36742916-1F47F7B6-19E4-4F9C-96A8-C3F5D3BC05B2Q36783865-2D14ED0C-38EE-4D53-B43C-BF0E0268AFF0Q36800422-19938D1B-76DC-4EF7-AB4C-AFC49A5471A3Q37172662-41FB9E3E-65D1-4507-A582-987195F5AF51Q37367934-B307A3D2-998B-47AF-AE94-BF00FB1F3959Q37617567-DD8B062D-A080-4EBB-9EE5-F7A4DD11BC4DQ37771443-7C7B3642-0D25-404B-8BD9-7ECB8B078234Q37929513-0FD10E12-2BC1-417A-92E3-ABFE65DC1349Q37960149-C6FF056C-F840-46C5-B817-1FA54CB28F02Q37993945-7092F3BF-B30E-4676-96D1-F6B995393E1CQ38033468-6988CF73-CCD8-4725-A133-6DDCD7489CBDQ38072259-10FD41A3-648C-4D2F-B7A6-046CB75A10F2Q38073629-204A8A29-9ECB-4C69-949B-1988D5C99981Q38113092-087831A7-4BC6-4FDF-A9CC-693D4345D6F2Q38200704-DD4963A0-ABCD-42DD-B641-357D445DFFC6Q38524435-E443FE83-2B92-411C-81FC-6661A3C8875B
P2860
Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging cardiovascular action ...... fits beyond glycaemic control?
@en
Emerging cardiovascular action ...... fits beyond glycaemic control?
@nl
type
label
Emerging cardiovascular action ...... fits beyond glycaemic control?
@en
Emerging cardiovascular action ...... fits beyond glycaemic control?
@nl
prefLabel
Emerging cardiovascular action ...... fits beyond glycaemic control?
@en
Emerging cardiovascular action ...... fits beyond glycaemic control?
@nl
P2093
P2860
P1476
Emerging cardiovascular action ...... fits beyond glycaemic control?
@en
P2093
Brian D Green
David J Grieve
Roslyn S Cassidy
P2860
P304
P356
10.1111/J.1476-5381.2009.00376.X
P407
P577
2009-08-01T00:00:00Z